Advanced Circulatory Systems Inc (ACSI) devices, ResQPump, and the ResQPOD impedance threshold device, when used together could save the lives of cardiac arrest patients each year if implemented nationwide, according to the clinical trial results published in 'The Lancet' edition.

According to the study, higher percentage of patients who experienced out-of-hospital cardiac arrest survived after receiving active compression decompression cardiopulmonary resuscitation (ACD CPR) performed with the ResQPump, and the ResQPOD device, as compared to those receiving conventional, manual CPR performed with a pair of hands.

Funded by the National Institutes of Health (NIH) and sponsored by ACSI, the trial compared survival rates among a control group of 813 cardiac arrest patients receiving standard cardiopulmonary resuscitation (CPR), to an intervention group of 840 patients receiving ACD CPR, performed using the ResQPump, with an impedance threshold device (ITD), the ResQPOD.

The ResQPOD is an impedance threshold device (ITD) that selectively prevents unnecessary respiratory gases from entering the chest during the chest wall recoil phase of CPR and is attached within the ventilation circuit between the airway device and the ventilation source.

The ResQPump is a hand-held, active compression decompression (ACD) CPR device placed in the same position on the sternum as the hands and enabling rescuers to perform similar chest compressions as in conventional CPR.